Alcon Shares Rise After Dry-Eye Care Drug Shows Promising Results
By David Sachs
Shares in Alcon rose Wednesday after the Swiss company reported positive results for a dry-eye disease treatment undergoing two trials.
At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46. They had risen as high as CHF70.20
The Swiss eye-care company said late Tuesday that it achieved its primary goals with statistical significance for AR-15512, a candidate to treat dry-eye disease. It plans to file a new drug application with the U.S. Food and Drug Administration in mid-2024, it said.
The drug works demonstrably faster than competitors Restasis and Xiidra, positioning it to grab a significant piece of the U.S. market, Citi analysts said in a research note on Wednesday. Analysts estimated an earnings-per-share upside of around 3% for every $100 million in sales by 2026. The dry-eye treatment market in the U.S., where Alcon is also listed, is worth between $1.5 billion and $2 billion, Citi said.
Alcon also met secondary goals, including rapid and sustained tear production, it said.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 10, 2024 03:57 ET (08:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now